Merck & Co. Inc. is seeking to sever the cases of two plaintiffs that a judge plans to try together in the Vioxx trial set to begin Monday in Atlantic City.

While both plaintiffs allege to have suffered heart attacks after taking the drug for more than two years before, the drug maker argues that the facts, witness testimony and scientific and marketing evidence presented by each would confuse jurors to Merck’s disadvantage.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]